Testosterone Therapy for the Treatment of Age-Related Hypogonadism: Risks with Uncertain Benefits.

ABSTRACT: Testosterone replacement therapy has been approved in the United States since the 1950s for men with "classical" hypogonadism. These men have specific and well-recognized hypothalamic, pituitary, or testicular conditions leading to deficient or absent endogenous testosterone. A more controversial treatment population is aging men, many with comorbidities, who have low serum testosterone concentrations compared with young healthy men and who do not have the well-recognized medical conditions that cause "classical" hypogonadism. Testosterone continues to be widely used in these men with "age-related hypogonadism" even though the benefits of testosterone for this use are uncertain and there are important risks, including a potential risk of major adverse cardiac events for the testosterone cl

SUBMITTER: Nguyen CP 

PROVIDER: S-EPMC8142681 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature